What is the difference between Capisetide/Tunicate and Inarisep

Capivasertib and Inavolisib are targeted therapy drugs that specifically target key nodes in the PI3K/AKT signaling pathway and are mainly used to treat patients with HR-positive/HER2-negative breast cancer. Although their targets of action are similar, there are significant differences in molecular mechanisms, clinical applications, efficacy, safety, and drug management.

Carpisetin is an oral AKT inhibitor, which mainly inhibits the proliferation and survival of tumor cells by inhibiting the activity of AKT kinase and blocking the PI3K/AKT pathway. Its molecular structure design makes it have inhibitory effects on AKT1, AKT2 and AKT3 isoforms, and has a weak inhibitory effect on PI3Kα, β, γ and δ isoforms. This selectivity makes it possible to reduce the impact on other PI3K isoforms during treatment, thereby reducing the risk of certain side effects.

Inaliset is a highly selective PI3Kα inhibitor, which mainly inhibits the activity of PI3Kα isoforms and reduces the activation of the downstream AKT pathway. Its molecular structure is designed to have a stronger inhibitory effect on PI3Kα, but a weaker inhibitory effect on PI3Kβ, γ, and δ isoforms. This high selectivity may make it more effective in specific tumor types.

In terms of clinical application, capicipositi has been approved in combination with fulvestrant for the treatment of patients with HR-positive/HER2-negative breast cancer, especially those with PIK3CA, AKT1 or PTEN gene mutations. Its clinical studies have shown that combination therapy can significantly extend progression-free survival (PFS) and overall survival (OS) compared with fulvestrant alone.

Inaliset, used in combination with Palbociclib (palbociclib) and fulvestrant, has been approved by the FDA in 2024 for the treatment of patients with HR-positive/HER2-negative breast cancer, especially those with PIK3CA mutations. Its clinical study showed that the triple therapy group was better than the control group using palbociclib and fulvestrant alone in terms of PFS and OS.

In terms of efficacy, both capicipositi and inaliset show good anti-tumor activity, but due to their different mechanisms of action, they may show different efficacy in different patient groups. For example, carpiseti may be beneficialPatients with AKT mutations are more effective, while inalise may be more effective in patients with PIK3CA mutations.

In terms of safety, common side effects of carpiseti include diarrhea, skin reactions (such as rash), high blood sugar, anemia, etc. The incidence of hyperglycemia is low, but the incidence of diarrhea is relatively high. Common side effects of inariside include hyperglycemia, skin reactions, gastrointestinal reactions (such as stomatitis, nausea, vomiting), etc. It has a higher incidence of hyperglycemia but a lower incidence of skin reactions.

In terms of drug management, the dosing regimen of capizetin is usually twice daily orally, and the course of treatment is adjusted based on the patient's tolerance and efficacy. Inaliset is administered orally once daily, usually in combination with palbociclib and fulvestrant. Both dosage regimens need to be individually adjusted based on the specific conditions of the patient.

In general, capicetine and inaliset, as targeted therapeutic drugs of the PI3K/AKT pathway, have important clinical value in the treatment of HR-positive/HER2-negative breast cancer. Although their targets of action are similar, there are significant differences in molecular mechanisms, clinical applications, efficacy, safety, and drug management.

Reference materials:https://www.drugs.com/mtm/capivasertib.html